Endocrinologic/Metabolic Drugs Panel Renewed

Federal Register notice: FDA has renewed for two years the charter of the Endocrinologic and Metabolic Drugs Advisory Committee. The new charter will now be in effect until 8/27/2020. To view the notice, click here.

Read more